Marshall Wace, LLP Allakos Inc. Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $103,354 - $198,777	24,036 Added 43.09%	79,818 $355,000
Q4 2022 Feb 14, 2023	BUY	$5.66 - $8.42 $315,726 - $469,684	55,782 New	55,782 $469,000
Q2 2022 Aug 15, 2022	SELL	$2.6 - $6.14 $213,184 - $503,443	-81,994 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $416,529 - $804,361	81,994 New	81,994 $467,000
Q1 2021 May 17, 2021	SELL	$109.73 - $153.66 $180,725 - $253,078	-1,647 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$79.58 - $152.45 $131,068 - $251,085	1,647 New	1,647 $231,000
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $24,736 - $51,924	-556 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $17,236 - $49,889	556 New	556 $44,000
Q2 2019 Aug 14, 2019	SELL	$36.0 - $44.73 $315,684 - $392,237	-8,769 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$33.79 - $51.99 $296,304 - $455,900	8,769 New	8,769 $355,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $81.3M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.